Loading…
Fresenius Medical Care AG is projected to rise to $33.68 by 2027, a +31% move from its current price of $25.70. FMS is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $25.38 | $25.71 | $26.04 | +0.02% |
| Aug 2 | $25.25 | $25.71 | $26.18 | +0.04% |
| Aug 3 | $25.15 | $25.72 | $26.30 | +0.06% |
| Aug 4 | $25.07 | $25.72 | $26.39 | +0.08% |
| Aug 5 | $25.00 | $25.73 | $26.48 | +0.11% |
| Aug 6 | $24.94 | $25.73 | $26.56 | +0.13% |
| Aug 7 | $24.88 | $25.74 | $26.63 | +0.15% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $24.88 | $25.74 | $26.63 | +0.15% |
| Week 2 | $24.57 | $25.78 | $27.05 | +0.30% |
| Week 3 | $24.34 | $25.81 | $27.38 | +0.45% |
| Week 4 | $24.15 | $25.85 | $27.67 | +0.60% |
| Week 5 | $24.00 | $25.89 | $27.94 | +0.75% |
| Week 6 | $23.86 | $25.93 | $28.18 | +0.90% |
| Week 7 | $23.73 | $25.97 | $28.41 | +1.05% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company operates through Care Delivery and Care Enablement segments.
It also develops, manufactures, and distributes various health care products, including hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular specialty, ambulatory surgery center, physician nephrology practice management, pharmacy and other services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics, as well as through local sales forces, independent distributors, dealers, and sales agents.
The company was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
Fresenius Medical Care AG, ticker FMS, is a healthcare company focused on dialysis services. The current price is $24.09. It has a market capitalization of $12.94B and is ranked 774 by market cap. The stock sits in a mid-cap space with ongoing attention from investors as reflected in its technical setup and forward-looking forecast.
A major floor 21.4% below — a decisive break under it would weaken the trend.
The nearest floor, 12.0% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 8.0% above — clearing it would confirm fresh momentum.
Key FMS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of FMS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $24.95 | Buy | $25.04 | Buy |
| MA 10 | $24.64 | Buy | $24.74 | Buy |
| MA 20 | $24.32 | Buy | $24.33 | Buy |
| MA 50 | $23.19 | Buy | $23.59 | Buy |
| MA 100 | $22.83 | Buy | $23.29 | Buy |
| MA 200 | $23.40 | Buy | $23.46 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 72.23 | Sell |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 242.04 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.07 | Buy |
| ROC (12) | 6.46 | Buy |
| Bollinger %B (20,2) | 1.21 | Sell |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.28 | Buy |
| Awesome (5,34) | 1.08 | Buy |
| Ultimate (7,14,28) | 73.24 | Sell |
| Momentum (10) | 1.61 | Buy |
| Aroon Osc (25) | 84.00 | Buy |
| Hull MA (9) | 25.20 | Buy |
| ADX (14) | 23.61 | Buy |
| ATR (14) | 0.28 | Info |
The 30-day technical picture is bullish, with RSI14 at 60. The stock trades above the 50-day simple moving average of $22.57 and near the 200-day simple moving average of $23.50. Support is indicated at $20.90 and resistance at $24.45, framing a near-term range.
The 30-day price range runs from $22.11 to $26.24, reflecting a modestly constructive drift in recent trading. The annualized volatility is 20, signaling notable price movement potential over time.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $20.19 | $25.70 | $34.44 | 0% | Neutral | |
| $27.61 | $33.68 | $42.92 | +31% | Bullish | |
| $34.86 | $43.33 | $56.73 | +69% | Bullish | |
| $40.83 | $51.54 | $68.94 | +101% | Bullish | |
| $44.76 | $57.26 | $77.98 | +123% | Bullish | |
| $50.32 | $65.16 | $90.16 | +154% | Bullish | |
| $52.10 | $68.23 | $95.75 | +165% | Bullish | |
| $57.72 | $76.40 | $108.61 | +197% | Bullish | |
| $71.96 | $96.19 | $138.39 | +274% | Bullish | |
| $79.39 | $107.13 | $155.85 | +317% | Bullish | |
| $112.52 | $158.38 | $241.49 | +516% | Bullish | |
| $245.35 | $370.41 | $605.45 | +13.4x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $20.19 | $25.70 | $29.94 | +0.00% |
| August 2026 | $22.18 | $25.86 | $30.73 | +0.61% |
| September 2026 | $22.34 | $26.20 | $31.43 | +1.34% |
| October 2026 | $23.33 | $27.48 | $33.21 | +4.89% |
| November 2026 | $23.91 | $28.27 | $34.37 | +2.86% |
| December 2026 | $23.74 | $28.18 | $34.44 | -0.33% |
Click any year to see its month-by-month FMS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect FMS to range from $20.19 to $34.44 through 2026. The $25.70 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The FMS price prediction for 2027 points to an average of $33.68 (low $27.61, high $42.92) — a potential gain of +31% on today's $25.70. Momentum favours further upside here.
In 2028, FMS is projected to trade between $34.86 and $56.73, averaging $43.33 — a potential gain of +69% from today's $25.70. That is up +29% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Fresenius Medical Care AG's 2029 outlook centres on $51.54, within a $40.83 to $68.94 range. That is up +19% on the projected 2028 average. That marks a +101% change versus current levels. Momentum favours further upside here.
By 2030, FMS could reach as high as $77.98, with a base case around $57.26 and support toward $44.76 — roughly +123% from $25.70. Buyers look set to stay in control over this stretch.
Expect FMS to range from $50.32 to $90.16 through 2031. The $65.16 average target implies a +154% move from current prices. That is up +14% on the projected 2030 average. Momentum favours further upside here.
The FMS price prediction for 2032 points to an average of $68.23 (low $52.10, high $95.75) — a potential gain of +165% on today's $25.70. Buyers look set to stay in control over this stretch.
In 2033, FMS is projected to trade between $57.72 and $108.61, averaging $76.40 — a potential gain of +197% from today's $25.70. That is up +12% on the projected 2032 average. Momentum favours further upside here.
Fresenius Medical Care AG's 2034 outlook centres on $96.19, within a $71.96 to $138.39 range. That is up +26% on the projected 2033 average. That marks a +274% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, FMS could reach as high as $155.85, with a base case around $107.13 and support toward $79.39 — roughly +317% from $25.70. Momentum favours further upside here.
Expect FMS to range from $112.52 to $241.49 through 2040. The $158.38 average target implies a +516% move from current prices. That is up +48% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The FMS price prediction for 2050 points to an average of $370.41 (low $245.35, high $605.45) — a potential gain of +13.4x on today's $25.70. Momentum favours further upside here.
Investing $1,000 in FMS today (≈ 38.910506 FMS) could be worth
$14,412.67
+$13,412.67 (+1341%) by 2050 · US Dollar
Based on the average projected FMS price of $370.41 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in FMSwould be worth at today's price.
$1,000 invested in FMS on Jul 30, 2025 (≈ 38.759691 FMS) would be worth
$996.12
-$3.88 (-0.4%) today · 1.00× · US Dollar
Based on a FMS entry price of $25.8 vs. today's $25.7.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $24.44 | $1,051.55 | +5.2% |
| 1 month ago | $22.61 | $1,136.67 | +13.7% |
| 3 months ago | $22.49 | $1,142.73 | +14.3% |
| 6 months ago | $22.7 | $1,132.16 | +13.2% |
| 1 year ago | $25.8 | $996.12 | -0.4% |
| All time (5.0y) ago | $38.36 | $669.97 | -33.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our FMS forecast.
Our base-case forecast reaches $51.00 around 2029.
Implied market cap at $51.00: $27.39B
The multi-year forecast shows a path of rising averages and growing upside. In 2026, the min is $20.19, the avg is $24.09, and the max is $31.96 with an ROI of 0 and a neutral sentiment. By 2030, the min is $38.50, the avg is $49.28, and the max is $67.16 with an ROI of 104.6 and bullish sentiment.
In 2040, the min is $84.73, the avg is $119.30, and the max is $181.96 with an ROI of 395.2 and bullish sentiment. In 2050, the min is $179.28, the avg is $270.72, and the max is $442.62 with an ROI of 1023.8 and bullish sentiment. These figures imply meaningful upside over a long horizon, though they are estimates, not guarantees.
The outlook highlights progressively higher average prices and ROIs, culminating in substantial longer-term upside.
Tap a question to reveal the answer.
2030 forecast shows min $38.50, avg $49.28, max $67.16, ROI 104.6%, sentiment BULLISH.
Forecasts indicate rising averages and bullish sentiment from 2027 onward, with increasing ROI (e.g., 2027 avg $30.67, ROI 27.3%; 2028 avg $37.88, ROI 57.2%; 2029 avg $44.80, ROI 86%; 2030 avg $49.28, ROI 104.6%). These are estimates, not guarantees.
Yes, the 2040 maximum forecast is $181.96, exceeding $100, with 2040 avg $119.30 and ROI 395.2%.
The current price is $24.09.
30-day range is $22.11 to $26.24. The stock has an annualized volatility figure of 20 and a bullish intermediate sentiment in the near term.
Fresenius Medical Care AG Community Discussion
0Share your Fresenius Medical Care AG price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.